Rethinking Denosumab Discontinuation: State of the Art and Proposal of an Innovative Algorithm for Fracture Risk Management Post-Denosumab
Background. Denosumab discontinuation is associated with a sharp rebound in bone turnover and increased incidence of (multiple vertebral) fractures within months. Current strategies often rely on a fixed serum C-terminal telopeptide (CTX) threshold to
Authors
- Luca Acanfora
- Filippo Maria Bolamperti
- Alberto Vassallo (ORCID: https://orcid.org/0009-0004-8633-7700)
- Matteo Acanfora (ORCID: https://orcid.org/0009-0004-8362-9249)
- Gaia Tamellini
Institutions
- University of Pavia (IT)
- United Hospital (US)
- IRCCS Ospedale San Raffaele (IT)
Publication Details
- Published
- 2025-08-26
- DOI
- https://doi.org/10.22541/au.175624415.54668684/v1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00